NCT01701336View on ClinicalTrials.gov

Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

February 28, 2013

Conditions
Hepatitis C
Interventions
BIOLOGICAL

Ad6NSmut, MVA-NSmut

2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination

Trial Locations (2)

56126

Azienda Ospedaliera Universitaria di Pisa. Ospedale di Cisanello, Pisa

Azienda Ospedaliera Universitaria Pisana. Ospedale di Santa Chiara, Pisa

All Listed Sponsors
collaborator

European Commission

OTHER

lead

ReiThera Srl

INDUSTRY

NCT01701336 - Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients | Biotech Hunter | Biotech Hunter